OUR DRUG DISCOVERY APPROACHES
Flexible, patentable approaches to discover patentable drug leads
- Natural compounds from microorganisms (such as fungi and bacteria) were chemically refined for millions of years, yet the vast majority remain silent in their genomes – ENDOBIOS aims to trigger their production.
- Our proprietary methods for inducing microbial bioactive natural products aim to find new antibiotics and treatments for epilepsy and pain relief, including the validation of an innovative approach to the treatment of certain sub-types of cancer.
PROPRIETARY METHOD FOR THE DISCOVERY OF CRYPTIC ANTIBIOTICS FROM MICROBES
Disruptive method for activating cryptic antibiotics from microbes against gram-negative antibiotic-multiresistant bacterial pathogens
Already with a proof of concept in antibiosis induction in bacterial and fungal extracts, “ENDOBAC” disruptive technology was developed after the discovery of compounds that are perceived by environmental fungi and bacteria (likely other microorganisms like microalgae) as a bacterial attack.
“ENDOBAC” is a disruptive method for the induction of new, cryptic antibiotics from microbial sources, to be exploited in-house and in collaboration with R&D centres, pharma, agro or cosmetic companies interested in discovering and maturing antibiotic leads into marketable products.
Read more about Antibiotic Multiresistant Pathogenic Bacteria and our method in the Scientific Awareness section.
VALIDATION OF A NEW BIOLOGICAL TARGET AGAINST PATHOGENIC BACTERIA
An unforeseen bacterial mechanism that could serve as screening platform for the future discovery of new antibiotics
Based on our intellectual property in the field of endosymbiotic biology, we have identified an unexplored bacterial biological system that is expected to reveal natural genetic switches that pause bacterial division mechanisms. Our aim is to validate these new targets as platforms for the future discovery of new solutions against antibiotic-multiresistant bacteria (more to follow).
SCREENING FOR CRYPTIC MICROBIAL NEUROPATHIC AGENTS
Disruptive method for activating the production of cryptic microbial (fungi and bacteria) compounds against neuropathies
ENDOBIOS is on track to validate a high throughput screening (HTS) disruptive method for the discovery of new microbial-derived drug candidates against multiple neuropathies, challenging microbial cultures (starting from fungi and bacterial culture collections) in unprecedented new ways. Once validated, the intellectual property will serve as base for the discovery of new neuropathic agents that are silent in microbial genomes.
Why would microbes have molecules with an affinity to the human nervous system? Microbes served as templates for more complex forms of Life, including our nervous system. As an example, the description and classification of Transient Receptor Potential (TRP) ion channels is usually focused on those in mammals. However, in reality, TRP channel genes are found in fungal genomes as well as those of ciliates, flagellates, slime moulds, Trypanosome, Leishmania, and so on, indicating an early origin. Read more about Central Nervous System (CNS) disorders in the Scientific Awareness section.
ENDO-EVOLUTION & DISEASES.
A disruptive concept for diagnostics and custom treatment of several diseases influenced by intracellular bacteria
Our paradigm-shifting discoveries are being validated to determine an unexpected influence of endosymbioses on evolutionary biological systems.
Read more about Endosymbioses in the Scientific Awareness section.
CUSTOM DISRUPTIVE METHODS
Our innovations in the induction of cryptic natural compounds from microbial sources can be custom-translated against other diseases, e.g. antifungals or biomolecular targets.
For more information about our approaches, see the Cryptic Bioactive Microbial Natural Products section in the Scientific Awareness section.
